Gwendolyn H.M.J. Griffioen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gwendolyn H.M.J. Griffioen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Suresh Senan
Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1117 Amsterdam, The Netherlands
5 shared publications - Berend Jan Slotman
Department of Radiation Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
4 shared publications Max Dahele
Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands
2 shared publications- Alexander V. Louie
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada
1 shared publication Andrew Warner
1 shared publicationBen J. Slotman
1 shared publication
Latest Publications
- 1 April 2015
- Published by Elsevier in Lung Cancer
- Vol. 88 (1) , 94-99
Second primary lung cancers following a diagnosis of primary head and neck cancer
- 1 April 2015
- Published by Elsevier in Lung Cancer
- Vol. 88 (1) , 94-99
Second primary lung cancers following a diagnosis of primary head and neck cancer
- 1 August 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (8) , 1222-1225
A Brief Report on Outcomes of Stereotactic Ablative Radiotherapy for a Second Primary Lung Cancer: Evidence in Support of Routine CT Surveillance
- 1 August 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (8) , 1222-1225
A Brief Report on Outcomes of Stereotactic Ablative Radiotherapy for a Second Primary Lung Cancer: Evidence in Support of Routine CT Surveillance
- 1 March 2014
- Published by Elsevier in Lung Cancer
- Vol. 83 (3) , 356-362
High-dose, conventionally fractionated thoracic reirradiation for lung tumors
- 1 March 2014
- Published by Elsevier in Lung Cancer
- Vol. 83 (3) , 356-362
High-dose, conventionally fractionated thoracic reirradiation for lung tumors
- 1 October 2013
- Published by Elsevier in Lung Cancer
- Vol. 82 (1) , 95-102
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors
- 1 October 2013
- Published by Elsevier in Lung Cancer
- Vol. 82 (1) , 95-102
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors
- Open Access
- 23 July 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 305
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.
- 23 July 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 305
Open AccessStereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.